# Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

> **NCT00759239** · PHASE4 · COMPLETED · sponsor: **Alcon Research** · enrollment: 36 (actual)

## Conditions studied

- Open-angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** Travoprost 0.004% / Timolol maleate 0.5%
- **DRUG:** Travoprost 0.004% / Timolol maleate 0.5%

## Key facts

- **NCT ID:** NCT00759239
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2016-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00759239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00759239, "Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00759239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*